[go: up one dir, main page]

AU726143B2 - Methods for treatment of allergic diseases with IgE - Google Patents

Methods for treatment of allergic diseases with IgE Download PDF

Info

Publication number
AU726143B2
AU726143B2 AU19875/97A AU1987597A AU726143B2 AU 726143 B2 AU726143 B2 AU 726143B2 AU 19875/97 A AU19875/97 A AU 19875/97A AU 1987597 A AU1987597 A AU 1987597A AU 726143 B2 AU726143 B2 AU 726143B2
Authority
AU
Australia
Prior art keywords
ige
patient
serum
week
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19875/97A
Other languages
English (en)
Other versions
AU1987597A (en
Inventor
Daniel C. Adelman
Donald W. Macglashan Jr.
James D. Reimann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Johns Hopkins University
Original Assignee
Genentech Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Johns Hopkins University filed Critical Genentech Inc
Publication of AU1987597A publication Critical patent/AU1987597A/en
Application granted granted Critical
Publication of AU726143B2 publication Critical patent/AU726143B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU19875/97A 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with IgE Ceased AU726143B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12
US08/614220 1996-03-12
PCT/US1997/003443 WO1997033616A1 (en) 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with ige

Publications (2)

Publication Number Publication Date
AU1987597A AU1987597A (en) 1997-10-01
AU726143B2 true AU726143B2 (en) 2000-11-02

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19875/97A Ceased AU726143B2 (en) 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with IgE

Country Status (8)

Country Link
EP (1) EP0904108A1 (es)
JP (1) JP2001505181A (es)
AR (1) AR006202A1 (es)
AU (1) AU726143B2 (es)
CA (1) CA2246427A1 (es)
IL (1) IL126113A0 (es)
WO (1) WO1997033616A1 (es)
ZA (1) ZA971607B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US20020018778A1 (en) * 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
CA2445269A1 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
EP0550020A2 (en) * 1991-12-24 1993-07-07 Snow Brand Milk Products Co., Ltd. Anti-human IgE monoclonal antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
EP0550020A2 (en) * 1991-12-24 1993-07-07 Snow Brand Milk Products Co., Ltd. Anti-human IgE monoclonal antibodies

Also Published As

Publication number Publication date
EP0904108A1 (en) 1999-03-31
CA2246427A1 (en) 1997-09-18
JP2001505181A (ja) 2001-04-17
AR006202A1 (es) 1999-08-11
AU1987597A (en) 1997-10-01
IL126113A0 (en) 1999-05-09
WO1997033616A1 (en) 1997-09-18
ZA971607B (en) 1998-08-25

Similar Documents

Publication Publication Date Title
EP0841946B1 (en) Methods for treatment of allergic asthma
EP0739214B1 (en) A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
Oshiba et al. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice.
US20110311520A1 (en) Methods for treatment of allergic asthma
MXPA98000760A (es) Metodos para el tratamiento del asma alergica
AU726143B2 (en) Methods for treatment of allergic diseases with IgE
EP1390067A1 (en) Compositions for use in treating ige-associated disorders
Mankad et al. Omalizumab: other indications and unanswered questions
KR20030022134A (ko) 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
AU2026200182A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
Di Domenico et al. Xolair in asthma therapy: an overview
Cingi et al. Update on the medical treatment of allergic rhinitis
Larsen The pulmonary late-phase response
Hamelmann et al. Anti-IgE therapy
WO1997010004A1 (en) Methods for treatment of interstitial cystitis
Milano et al. Recent Patents on Xolair, a New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma
Concas et al. Omalizumab therapy in the management of severe allergic asthma
US9795618B2 (en) Methods and compositions for suppressing IgE-mediated anaphylaxis
Ross et al. AMERICAN ACADEMY OF ALLERGY
WO2003082217A2 (en) Ctla4 compositions in the treatment of autism
Nadeau 40 Anti–Immunoglobulin E Therapy
Capron et al. 11.2 IgE Receptors on Inflammatory Cells
Francois et al. Workshop IV

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired